The Ozempic Baby Boom Is Real
Social media has been buzzing about "Ozempic babies" for over a year, but the phenomenon is now backed by hard data. A study published in March 2026 in the journal Fertility and Sterility found that women taking GLP-1 receptor agonists experienced a 40% increase in fertility markers compared to matched controls who lost similar amounts of weight through diet and exercise alone.
The finding suggests that GLP-1 drugs may have direct fertility-enhancing effects beyond those attributable to weight loss, though the exact mechanisms remain unclear.
Why GLP-1 Drugs Affect Fertility
Obesity is a well-established cause of reduced fertility. Excess body fat disrupts hormonal balance, can impair ovulation, and is associated with conditions like polycystic ovary syndrome (PCOS). Weight loss, by any means, typically improves fertility. But the GLP-1 effect appears to go further.
"We are seeing fertility improvements that exceed what we would predict from weight loss alone," said Dr. Jennifer Garrison, a reproductive scientist at the Buck Institute for Research on Aging. "The GLP-1 receptor is expressed in the reproductive system, and these drugs may be directly modulating ovarian function."
- Improved ovulation: Women with PCOS on GLP-1 drugs showed normalized ovulation patterns in 68% of cases
- Hormonal rebalancing: Testosterone levels in women with PCOS decreased by an average of 35%
- Reduced inflammation: Lower systemic inflammation may improve implantation rates
- Improved insulin sensitivity: Better glucose regulation supports healthy ovarian function
The Safety Concern
Here is the critical problem: GLP-1 drugs are not approved for use during pregnancy. Both Novo Nordisk and Eli Lilly recommend discontinuing semaglutide and tirzepatide at least two months before attempting to conceive. Animal studies have shown potential risks including fetal growth restriction and skeletal abnormalities at high doses.
"The disconnect is dangerous," said Dr. Christina Han, director of maternal-fetal medicine at UCLA. "These drugs are making women more fertile while simultaneously posing potential risks if they become pregnant while still taking them."
The FDA has classified semaglutide as pregnancy category X in early development and now carries a boxed warning about reproductive risks. However, human data remains extremely limited.
What the Pregnancy Data Shows
A Novo Nordisk registry tracking pregnancies that occurred during semaglutide use has enrolled over 2,800 cases since 2023. Preliminary data presented at the American College of Obstetricians and Gynecologists meeting shows:
- No statistically significant increase in major birth defects compared to the general population
- A slightly elevated rate of preterm birth (11.2% vs. 9.8% baseline)
- Lower rates of gestational diabetes, likely due to improved metabolic health
However, experts caution that registry data is subject to significant reporting bias and should not be considered definitive evidence of safety.
What Women Should Do
Healthcare providers recommend the following for women of reproductive age taking GLP-1 medications:
- Use reliable contraception: Do not rely on the assumption that obesity-related infertility will prevent pregnancy
- Plan ahead: If considering pregnancy, work with your doctor to taper off GLP-1 drugs at least two months before trying to conceive
- If pregnant on a GLP-1: Stop the medication immediately and contact your healthcare provider, but do not panic
- Discuss alternatives: Your provider can help transition to pregnancy-safe weight management strategies
"The message is not that GLP-1 drugs are dangerous in pregnancy," said Dr. Han. "The message is that we do not have enough data to say they are safe, and the precautionary principle should apply."
